Harvard Bioscience Profit Margin

The latest profit margin for HBIO is -11.86% as of June 2026. That compares with -64.68% in the prior-year period — up 81.7% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Harvard Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, HBIO's profit margin moved from -64.68% to -11.86% — a 81.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harvard Bioscience's valuation or profitability profile.

Against Healthcare companies, HBIO currently prints -11.86% for profit margin, while the sector average sits near 13.89%. That is roughly 185.4% below the sector mean. Large gaps often invite a closer look at Harvard Bioscience's growth, margins, and balance sheet.

Profit Margin shows how effectively Harvard Bioscience converts resources into returns. At -11.86%, HBIO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -64.68% in the prior-year period — up 81.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HBIO's profit margin (-11.86%), review year-over-year change from -64.68%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.